Beacon Therapeutics reports promising 6-month data on laru-zova, showing visual function improvements in XLRP patients from the DAWN trial. Beacon Therapeutics announced promising interim results from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results